Prognostic factors in non-small cell lung cancer PDF Download

Author: Luciano Mutti
Publisher: Frontiers Media SA
ISBN: 2832520472
Category : Medical
Languages : en
Pages : 471

View

Book Description

Author: Richard J. Gralla
Publisher:
ISBN:
Category : Combined modality therapy
Languages : en
Pages : 160

View

Book Description

Author: Kristin Higgins
Publisher: Frontiers Media SA
ISBN: 2832510159
Category : Medical
Languages : en
Pages : 180

View

Book Description

Author: Paul Van Houtte
Publisher: Springer Science & Business Media
ISBN: 3642598242
Category : Medical
Languages : en
Pages : 280

View

Book Description
This volume provides a comprehensive account of the progress that has been made in the treatment of lung cancer. The various therapeutic approaches are documented and appraised, with particular emphasis being placed on the benefits of a multimodality strategy. A balance is sought between US and European perspectives, and all of the authors are recognized experts in the field.

Author: Jean-Paul Sculier
Publisher: Springer Science & Business Media
ISBN: 364218698X
Category : Medical
Languages : en
Pages : 442

View

Book Description
Lung cancer is the neoplastic disease with the highest mortality numbers in the world. The disease is very common in industrialized countries. Written with the practicing clinician in mind, this textbook offers numerous invaluable insights. Clinical evidence is summarized in the following fields: epidemiology, biology, pathology, diagnosis, treatment, and prognosis. Summarizes the clinician's approach to lung cancer International and multidisciplinary editorship Evidence-based conclusions summarize each chapter

Author: David J. Stewart
Publisher: Springer Science & Business Media
ISBN: 160761524X
Category : Medical
Languages : en
Pages : 544

View

Book Description
Defining the Lung Cancer Problem 1 Lung cancer is the leading cause of cancer death in the world. It kills almost as many Americans as cancers of the breast, prostate, colon, rectum, pancreas, and 2 kidney combined, and accounts for 28.6% of all US cancer deaths. With an increase in the 5-year relative survival rate from 13% to only 16% in the more than 2 30 years from 1974 to the present, it will take us another 840 years to eradicate lung cancer deaths if we do not improve the current rate of progress. As discussed in this text, lung cancer prevention has received substantial att- tion. The decrease in smoking in recent decades has helped, but smoking is not the only problem. Lung cancer in people who have never smoked is currently the 5th 3 leading cause of cancer death in the United States. Several factors contribute to the lethality of lung cancer, including the rapidity of tumor growth, advanced stage at diagnosis (due to nonspecificity of early sy- toms and the uncertain efficacy of screening), early development of metastases, and resistance to therapy. Several chapters in this book discuss new molecular targets that may be potentially exploitable in the future, as well as discussing our track record to date in exploiting them.

Author: Heine H. Hansen
Publisher: Springer Science & Business Media
ISBN: 146131593X
Category : Medical
Languages : en
Pages : 372

View

Book Description
The last volume dealing with lung cancer in this series in Cancer Treatment and Research was published in 1986 and entitled Lung Cancer: Basic and Clinical Aspects. The present book continues the outline of the previous volume by presenting up-to-date information on lung cancer in critical reviews of new important basic and clinical concepts of lung cancer. The present volume has broadened the scope by also including chapters dealing with issues such as epidemiology, prophylaxis, and histopathology of lung cancer. The content of the book thus reflects the increasing awareness of a global disease that is more and more in focus, not only scientifically but also politically. The latter fact results increasingly in changes in health legisla tion, with prevention measures influencing everyday life. The great interest in the disease is natural, considering that more than one patient dies from lung cancer every minute globally. The first chapter is from the Cancer Unit, WHO, Geneva, and describes in detail the epidemiologic features of lung cancer, which is the second most frequent cancer in the world with 660,500 new cases annually; it will soon surpass stomach cancer as the leader. Thirty-one percent of the cases occur in developing countries, where the increase is especially dramatic.

Author: J. Heide
Publisher: Karger Medical and Scientific Publishers
ISBN: 380559299X
Category : Medical
Languages : en
Pages : 219

View

Book Description
Under the auspices of the 12th International Symposium on Special Aspects in Radiotherapy 2008 in Berlin, acknowledged experts presented their perspectives on small and non-small cell lung cancer, reflecting the latest standards and engaging in controversies in the diagnosis and treatment of this disease.

Author: Junji Uchino
Publisher: Frontiers Media SA
ISBN: 2889745147
Category : Medical
Languages : en
Pages : 311

View

Book Description

Author: Branislav Jeremic
Publisher: Springer Science & Business Media
ISBN: 3540266321
Category : Medical
Languages : en
Pages : 510

View

Book Description
Although decades of laboratory and clinical research have led to incremental improvement in treatment outcome, lung cancer remains one of the most deadly diseases. This volume is unique in being devoted solely to the radiation oncology of lung cancer, and will be of great value to all who are involved in the diagnosis and treatment of the disease. Both non-small cell and small cell lung cancer are considered in detail. Current state-of-the-art treatment strategies and novel approaches that promise further improvements in outcome are explained and evaluated, with the aid of high-quality illustrations. Treatment-related toxicity is discussed, and further individual chapters focus on topics such as quality of life studies, prognostic factors and pitfalls in the design and analysis of clinical trials.